Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
eye irritation: in vitro / ex vivo
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2019-09-30 to 2019-11-18
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2019
Report date:
2019

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 492 (Reconstructed Human Cornea-like Epithelium (RhCE) Test Method for Identifying Chemicals Not Requiring Classification and Labelling for Eye Irritation or Serious Eye Damage)
Version / remarks:
adopted 18 June 2019
Deviations:
no
GLP compliance:
yes (incl. QA statement)

Test material

Constituent 1
Reference substance name:
Strontium dichlorophthalate
EC Number:
304-292-3
EC Name:
Strontium dichlorophthalate
Cas Number:
94248-20-1
Molecular formula:
C8H4Cl2O4.Sr
Test material form:
solid
Details on test material:
Strontium phthalate (HPLC): 0.51 w/w %
Strontium 3-chlorophthalate (HPLC): 0.73 w/w %
Strontium 3,6-dichlorophthalate (HPLC) / Strontium 4-chlorophthalate (HPLC): 10.59 w/w %
Strontium 3,4-dichlorophthalate (HPLC): 20.56 w/w %
Strontium 3,5-dichlorophthalate (HPLC): 0.66 w/w %
Strontium 3,4,6-trichlorophthalate (HPLC): 0.18 w/w %
Strontium 4,5-dichlorophthalate (HPLC): 60.59 w/w %
Strontium 3,4,5-trichlorophthalate (HPLC): 4.39 w/w %
Strontium tetrachlorophthalate (HPLC): 0 w/w %

Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Source and lot/batch number of test material:Dynamit Nobel GmbH Explosivstoff- und Systemtechnik, WE50352354
- Expiration date of the lot/batch: 28 November 2019
- Purity test date: 2 May 2019

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: room temperature
- Stability under storage conditions: stable under normal conditions

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test item (50 mg) was directly applied atop the EpiOcular™ tissue

Test animals / tissue source

Species:
human
Details on test animals or tissues and environmental conditions:
- Justification of the test method: This test uses the three-dimensional RhCE EpiOcular™ (MatTek). It consists of normal, human-derived epidermal keratinocytes and mimics the histological, morphological, biochemical and physiological properties of the human corneal epithelium. The MatTek EpiOcular™ model has been widely used as a research and testing model for many years.

Test system

Vehicle:
unchanged (no vehicle)
Controls:
yes, concurrent positive control
yes, concurrent negative control
Amount / concentration applied:
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 50 mg
Duration of treatment / exposure:
6 ± 0.25 h
Duration of post- treatment incubation (in vitro):
Post exposure post-soak plate: 25 ± 2 min at room temperature
Post exposure post-treatment plate: 18 ± 0.25 h at 37 ± 1 °C
Number of animals or in vitro replicates:
2 tissues per dose group
Details on study design:
- Details of the test procedure used:
Upon receipt of the EpiOcular™, the tissues were equilibrated in the 24-well shipment plate to room temperature for about 15 min. Then, the EpiOcular™ tissues were transferred into 6-well plates containing 1 mL pre-warmed assay medium per well and incubated for 1 h in a humidified incubator at 37 ± 2 °C, 5.0% CO2 / 95% air. Then the inserts were transferred into new 6-well plates containing 1 mL fresh assay medium per well and pre-incubated in a humidified incubator at 37 ± 2 °C, 5.0% CO2 / 95% air for 16 - 24 h.
After the overnight incubation the tissues were pre-treated with 20 μL of DPBS-buffer and incubated for 30 ± 2 min in a humidified incubator at 37 ± 2 °C, 5.0% CO2 / 95% air to mimic the wet conditions of the human eye.
Afterwards, the tissues were treated with each dose group in duplicate, starting with the negative and positive control. While the test item was applied, the tissue inserts were placed on a sterile surface. After dosing, the inserts were placed back into the culture medium. Then the 6-well plate(s) were incubated for 6 ± 0.25 h at 37 ± 2 °C, 5.0% CO2 / 95% air. At the end of the exposure period the test item and control substances were removed by extensively rinsing the tissue with DPBS. Excess DPBS was removed by decanting the insert and blotting bottom with blotting paper. After rinsing the inserts were transferred to and immersed in a prepared 12-well “post-soak plate“, containing 5 mL fresh pre-warmed assay medium per well and incubated for 25 ± 2 min at room temperature. Afterwards, the inserts were removed from the assay medium, the medium was decanted off the tissue and the tissues were blotted on blotting paper. The inserts were transferred to a new 6-well plate (post-treatment plate) containing 1 mL pre-warmed assay medium. The tissues were incubated for 18 ± 0.25 h at 37 ± 2°C, 5.0% CO2 / 95% air.
After this incubation period excess medium was removed by blotting bottom on absorbent paper before the inserts were transferred in a prepared 24-well “MTT assay plate” containing 0.3 mL pre-warmed MTT medium and further incubated for 3 h ± 15 min at 37 ± 2 °C, 5.0% CO2 / 95% air.
After the 3 h MTT incubation period the inserts were removed, the bottom of the inserts blotted on blotting paper, and then transferred into new 6-well “extraction plates“, containing 2 mL of isopropanol to extract only the bottom of the tissues. The extraction plates were sealed to inhibit isopropanol evaporation. Extraction was carried out immediately by shaking on an orbital plate shaker for 2 - 3 h at room temperature. At the end of the extraction period the tissues were not pierced to avoid contamination of the extract with remaining test item.
Then the inserts were discarded and the extracts were mixed three times using a pipette. If any visible cell/tissue fragments were in suspension, extracts were centrifuged to eliminate the fragments and avoid further possible interference with the absorbance readings.
For each tissue 2 x 200 μL aliquots of the extract were transferred into a 96-well plate and OD was measured at 570 nm using a filter band pass of maximum ± 30 nm in a plate spectrophotometer using isopropanol as a blank.
- RhCE tissue construct used, including batch number:
EpiOcular™ reconstructed human cornea-line epithelium (RhCE) model (MatTek), consisting of normal, human-derived epidermal keratinocytes which have been cultured to form a stratified, highly differentiated squamous epithelium morphologically similar to that found in a human cornea. The EpiOcular™ RhCE tissue construct consists of at least 3 viable layers of cells and a non-keratinized surface, showing a cornea-like structure analogous to that found in vivo.
The EpiOcular™ tissues were provided as kits (e.g. OCL-200-EIT; MatTek), consisting of the following components relevant for this study:
1x sealed 24-well plate containing 24 inserts with EpiOcular™ tissues on agarose (Lot No.: 30632)
1x bottle EpiOcularTM assay medium (Lot No.: 102819ISA)
1x bottle Ca2+/Mg2+-free DPBS buffer (Lot No.: 092419MSA)

- Doses of test chemical and control substances used:
1. Negative Control: 50 µL Aqua dest. (Sigma, Lot No.: RNBG4913)
2. Positive Control: 50 µL methyl acetate (CAS 79-20-9, Merck, Lot No. S6943111)
3. Test Item: 50 mg

- Duration and temperature of exposure, post-exposure immersion and post-exposure incubation periods (where applicable):
Exposure: 6 ± 0.25 h at 37 ± 1 °C, 5.0% CO2 / 95% air.
Post exposure post-soak plate: 25 ± 2 min at room temperature
Post exposure post-treatment plate: 18 ± 0.25 h at 37 ± 1 °C, 5.0% CO2 / 95% air

- Indication of controls used for direct MTT-reducers and/or colouring test chemicals:
See section "Pre-experiments" in box "Any other information on materials and methods incl. tables"

- Number of tissue replicates used per test chemical and controls (positive control, negative control, NSMTT, NSCliving and NSCkilled, if applicable): 2 tissues per group

- Wavelength and band pass (if applicable) used for quantifying MTT formazan, and linearity range of measuring device (e.g. spectrophotometer): 570 nm ± 30 nm

- Description of evaluation criteria used including the justification for the selection of the cut-off point for the prediction model:
Mean tissue viability (% negative control) <= 60 %: Irritant (I): UN GHS “Category 1” or “Category 2”
Mean tissue viability (% negative control) > 60%: Non-Irritant (NI): UN GHS “No Category”

- Reference to historical positive and negative control results demonstrating suitable run acceptance criteria:
Historical control data were generated from 2014-2018:
Absolute OD570 ± 30 nm NK: Mean: 1.697; SD: 0.275, n= 50
Relative Viability PC [%]: Mean: 24.9, SD: 12.9, n= 50
Difference of Viability [%]: Mean: 6.6, SD: 7.2, n= 216

Test Acceptance Criteria:
- mean absolute OD570 nm of the negative control is > 0.8 and < 2.8
- mean relative tissue viability of the positive control is < 50%
- relative tissue viability difference of replicate tissues is < 20%

Results and discussion

In vitro

Results
Irritation parameter:
other: Relative Tissue Viability [%]
Run / experiment:
Mean of replicates
Value:
92.4
Vehicle controls validity:
not examined
Negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
no indication of irritation
Other effects / acceptance of results:
ACCEPTANCE OF RESULTS:
- Acceptance criteria met for negative control: yes
- Acceptance criteria met for positive control: yes
- Range of historical values if different from the ones specified in the test guideline: see in box "Any other information on materials and methods incl. tables"

For individual results see Table 1 in box "Any other information on results incl. tables"

Any other information on results incl. tables

Table 1: Result of the Test Item Strontium dichlorophthalate

Name Negative Control Positive Control Test Item
Replicate Tissue 1 2 1 2 1 2
Absolute OD570 1.146 1.172 0.358 0.333 1.088 1.061
  1.145 1.182 0.359 0.334 1.086 1.072
Mean Absolute OD570 1.161****    0.346    1.077   
OD570 (Blank Corrected) 1.098 1.123 0.309 0.284 1.040 1.012
1.096 1.133 0.310 0.286 1.037 1.023
Mean OD570 of the Duplicates 1.097 1.128 0.310 0.285 1.038 1.018
(Blank Corrected)
Total Mean OD570 of the 2 Replicate Tissues (Blank Corrected) 1.112*    0.297    1.028   
SD of Mean OD570 of the Duplicates (Blank Corrected) 0.022    0.018    0.015   
Relative Tissue Viability [%] 98.6 101.4 27.9 25.6 93.4 91.5
 Difference [%]*** 2.8    2.3    1.9   
Mean Relative Tissue Viability [%] 100.0    26.7**    92.4   

*             Corrected mean OD570of the negative control corresponds to 100% absolute tissue viability

**            Mean relative tissue viability of the positive control is < 50%

***           Relative tissue viability difference of replicate tissues is < 20%

****       Mean absolute OD570of the negative control is > 0.8 and < 2.8

Table 2: Test Acceptance Criteria

Value Cut off pass/fail
Mean Absolute OD570 nm NC 1.161 0.8 < NC < 2.8 pass
Mean Relative Viability PC [%] 26.7 < 50% pass
Max. Difference of % Viability [%] 2.8 < 20% pass

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
In this study under the given conditions the test item showed no irritant effects. The test item is classified as “non-irritant“ in accordance with UN GHS “No Category” for eye irritation.
Executive summary:

In the present study the eye irritant potential of strontium dichlorophthalate was analysed according to OECD 492 using the three-dimensional human corneal epithelium model EpiOcular, consisting of normal, human-derived epidermal keratinocytes mimicking characteristics of the corneal epithelium. Hereby, 50 mg of the test item was applied directly atop the EpiOcular™ tissue. Cytotoxicity is expressed as the reduction of mitochondrial dehydrogenase activity measured by formazan production from MTT after a 6 hours exposure and 18 hours post-incubation period and compared to those of the concurrent negative controls. The test item showed non-specific reduction of MTT, but no colouring potential. Therefore, killed tissue controls were included and used for quantitative correction of results. The test item showed no irritant effects. The mean relative tissue viability of two replicates (% negative control) was > 60% (92.4%). Therefore, the test item is considered to be non-irritating to the eye in accordance with UN GHS “No Category”.